Clinical Trials Logo

Lymphoma, T-Cell, Peripheral clinical trials

View clinical trials related to Lymphoma, T-Cell, Peripheral.

Filter by:

NCT ID: NCT03728972 Active, not recruiting - Clinical trials for NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)

Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type

Start date: November 9, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test how well pembrolizumab shrinks Early-Stage NK/T-cell Lymphoma (ENKTL) in participants who have not yet received chemotherapy.

NCT ID: NCT03703375 Active, not recruiting - Lymphoma, T-Cell Clinical Trials

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Start date: November 6, 2018
Phase: Phase 3
Study type: Interventional

This study is a multicentric, open-label, randomized phase 3 trial. The study will be conducted in select countries in Europe and South Korea sponsored by LYSARC and in Japan sponsored by Celgene. There will be a combined enrollment target of 86 randomized patients, with approximately 14 randomized patients from Japan. The enrollment to the randomized study will start at European sites in parallel to a safety run-in part in Japan. A safety run-in will be conducted to confirm the tolerability of oral azacitidine at doses of 100 mg and 200 mg QD in Asian patients. Once oral azacitidine at 200 mg QD is confirmed as tolerable, Asian patients from Japan and South Korea will start to be randomized into the main study. Additional patients (non-randomized) are anticipated to enroll to the safety run-in.

NCT ID: NCT03629873 Active, not recruiting - Clinical trials for Mantle Cell Lymphoma

Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects

Start date: February 1, 2018
Phase: Phase 2
Study type: Interventional

This is a single arm, multi-center, open study to evaluating efficacy and safety of Chi-BEAC combining with auto-HSCT to treat aggressive lymphoma Subjects

NCT ID: NCT03598998 Active, not recruiting - Clinical trials for Anaplastic Large Cell Lymphoma

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

Start date: February 4, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of pralatrexate when given together with pembrolizumab and how well they work in treating patients with peripheral T-cell lymphomas that has come back after a period of improvement or has not responded to treatment. Pralatrexate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and pralatrexate may work better in treating patients with peripheral T-cell lymphomas.

NCT ID: NCT03593018 Active, not recruiting - Clinical trials for Refractory Angioimmunoblastic T-cell Lymphoma

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

Start date: November 9, 2018
Phase: Phase 3
Study type: Interventional

This study evaluates the efficacy of Oral azacitidine versus single-agent Investigator's Choice Therapy in patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma.

NCT ID: NCT03586999 Active, not recruiting - Clinical trials for Peripheral T Cell Lymphoma

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

Start date: November 7, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This regimen aims to become the first line treatment for peripheral T cell lymphoma, using nivolumab with the standard of care chemotherapy.

NCT ID: NCT03547700 Active, not recruiting - Clinical trials for Lymphoma, T-Cell, Peripheral

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

Start date: September 26, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Single arm phase I/II study of ixazomib and romidepsin in relapsed/refractory PTCL. Each cycle is 28 days. Patients will continue to receive therapy until progressive disease, unacceptable toxicity, or if any other withdrawal criteria are met. The phase I study includes three dose levels. The phase II study will include treatment with ixazomib and romidepsin at the MTD established in the Phase I study.

NCT ID: NCT03385226 Active, not recruiting - Clinical trials for Cutaneous T Cell Lymphoma

A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)

PORT
Start date: January 15, 2019
Phase: Phase 2
Study type: Interventional

Trial Subjects (patients), will receive single infusions of pembrolizumab every 3 weeks until disease progression or unacceptable toxicity develops. They will receive radiotherapy at week 12.

NCT ID: NCT03278782 Active, not recruiting - Clinical trials for Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

Start date: November 14, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects of pembrolizumab and romidepsin and to see how well they work in treating participants with peripheral T-cell lymphoma that has come back or that does not respond to treatment. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Romidepsin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and romidepsin may work better than pembrolizumab alone in treating participants with recurrent or refractory peripheral T-cell lymphoma.

NCT ID: NCT03113500 Active, not recruiting - Clinical trials for Angioimmunoblastic T-Cell Lymphoma

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Start date: May 25, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well brentuximab vedotin and combination chemotherapy work in treating patients with CD30-positive peripheral T-cell lymphoma. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, etoposide, and prednisone work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin and combination chemotherapy may work better in treating patients with CD30-positive peripheral T-cell lymphoma.